Air pollution inside Philly’s subway is much worse than on the streets
Three accused in 'Farmgate' Ramaphosa break-in appear in South African court
Equinor buys 9.8% stake in Orsted valued at $2.5 billion
Ex-Philippine President Duterte to run as mayor despite his drug killings legacy
Israeli soldiers kill Palestinian boy in West Bank confrontations, health ministry says
Pope Francis slams world's 'shameful inability' to stop Israel-Hamas war
Monster payrolls see 10-year Treasury yields top 4%
Wall Street futures down on rates rethink, geopolitical risks
Ravens claim wild overtime victory, Texans snatch last-second win and Jayden Daniels keeps rolling: NFL Week 5 Sunday review
Al Pacino reveals he nearly died of Covid-19 – and gives his thoughts on the afterlife
‘It was a massive thing’ to be England’s first Black football player, says Viv Anderson
(Reuters) -Pfizer's gene therapy for hemophilia A significantly cut the number of annual bleeding episodes in patients with the rare disorder in a late-stage study and performed better than the current standard treatment, the company said on Wednesday.
The data takes Pfizer one step closer to securing U.S. regulatory approval for a second gene therapy to treat hemophilia.
Pfizer had received the Food and Drug Administration's nod for Beqvez as a one-time gene therapy for hemophilia B, a less common type of the disorder, in April.
If approved, Pfizer's hemophilia A gene therapy will compete with BioMarin Pharmaceutical's one-time treatment Roctavian, which was approved in the U.S. last year and is priced at $2.9 million.
Currently, the standard-of-care treatment for hemophilia A patients is to undergo routine replacement of the clotting protein called Factor VIII.
Pfizer said its gene therapy for hemophilia A not only met the main goal of showing non-inferiority compared to the Factor VIII replacement therapy in reducing the annual bleeding rate in patients, but also showed superiority to the current standard treatment.
Data from the 75-patient pool also showed that 84% of patients who were given Pfizer's gene therapy had Factor VIII levels above 5% at 15 months post-infusion, the company said.
The company will present additional data at upcoming medical meetings, it added. Pfizer is co-developing the hemophilia A gene therapy from with Sangamo Therapeutics, from whom it had licensed the therapy.
People with hemophilia have a fault in a gene that regulates production of proteins called clotting factors, leading to spontaneous as well as severe bleeding following injuries or surgery.
Hemophilia A affects about 25 in every 100,000 male births worldwide, according to data cited by Pfizer, with majority of them having a moderate to severe form of the disease for which the gene therapy was tested.
(Reporting by Leroy Leo in Bengaluru; Editing by Shailesh Kuber)
